Q
Qunming Dong
Researcher at Vertex Pharmaceuticals
Publications - 12
Citations - 2772
Qunming Dong is an academic researcher from Vertex Pharmaceuticals. The author has contributed to research in topics: Ivacaftor & Cystic fibrosis. The author has an hindex of 6, co-authored 12 publications receiving 2452 citations.
Papers
More filters
Journal ArticleDOI
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
Bonnie W. Ramsey,Jane C. Davies,N. Gerard McElvaney,Elizabeth Tullis,Scott C. Bell,Pavel Dř evínek,Matthias Griese,Edward F. McKone,Claire E. Wainwright,Michael W. Konstan,Richard B. Moss,Felix Ratjen,Isabelle Sermet-Gaudelus,Steven M. Rowe,Qunming Dong,Sally Rodriguez,Karl Yen,Claudia L. Ordoñez,J. Stuart Elborn +18 more
TL;DR: Ivacaftor was associated with improvements in lung function at 2 weeks that were sustained through 48 weeks and substantial improvements were also observed in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, weight, and concentration of sweat chloride.
Journal ArticleDOI
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Frank J. Accurso,Steven M. Rowe,John P. Clancy,Michael P. Boyle,Jordan M. Dunitz,Peter R. Durie,Scott D. Sagel,Douglas B. Hornick,Michael W. Konstan,Scott H. Donaldson,Richard B. Moss,Joseph M. Pilewski,Ronald C. Rubenstein,Ahmet Uluer,Moira L. Aitken,Steven D. Freedman,Lynn M. Rose,Nicole Mayer-Hamblett,Qunming Dong,Jiuhong Zha,Anne Stone,Eric R. Olson,Claudia L. Ordoñez,Preston W. Campbell,Melissa A. Ashlock,Bonnie W. Ramsey +25 more
TL;DR: This study showed that VX-770 was associated with within-subject improvements in CFTR and lung function and provides support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis.
Journal ArticleDOI
Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data
Frank J. Accurso,Fredrick Van Goor,Jiuhong Zha,Anne Stone,Qunming Dong,Claudia L. Ordoñez,Steven M. Rowe,John P. Clancy,Michael W. Konstan,Heather Hoch,Sonya L. Heltshe,Sonya L. Heltshe,Bonnie W. Ramsey,Bonnie W. Ramsey,Preston W. Campbell,Melissa A. Ashlock +15 more
TL;DR: Analysis of changes in sweat chloride and NPD demonstrated that patients treated with ivacaftor achieved CFTR activity equivalent to approximately 35%–40% of normal, and Sweat chloride is useful in multicenter trials as a biomarker ofCFTR activity and to test the effect of CFTR potentiators.
Journal ArticleDOI
Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.
Steven M. Rowe,Bo Liu,Aubrey E. Hill,Heather Hathorne,Morty Cohen,John R. Beamer,Frank J. Accurso,Qunming Dong,Claudia L. Ordoñez,Anne Stone,Eric R. Olson,John P. Clancy +11 more
TL;DR: It is found that changes in CFTR activity were more readily detected than changes in ENaC activity, and that rigorous standardization was associated with relatively good within-subject reproducibility in placebo-treated subjects.